Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 20.98% is 24% above its 5-year average of 16.89%, near the high end of its 5-year range (1.80%–28.70%).
128.29% above its 12-month average of 9.19%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.90%.
RETURN ON ASSETS (ROA)
20.98%
RETURN ON ASSETS (ROA) AVG TTM
9.19%
RETURN ON ASSETS (ROA) AVG 3Y
12.55%
RETURN ON ASSETS (ROA) AVG 5Y
16.89%
RETURN ON ASSETS (ROA) AVG 10Y
22.08%
RETURN ON ASSETS (ROA) AVG 15Y
2.57%
RETURN ON ASSETS (ROA) AVG 20Y
-9.61%
CURRENT VS TTM AVG
+128.29%
CURRENT VS 3Y AVG
+67.17%
CURRENT VS 5Y AVG
+24.20%
CURRENT VS 10Y AVG
-5.00%
CURRENT VS 15Y AVG
+715.50%
CURRENT VS 20Y AVG
+318.39%
SECTOR MEDIAN · HEALTHCARE
-30.73%
median of 722 covered companies
CURRENT VS SECTOR MEDIAN
+168.28%
vs the sector median at left
Innoviva, Inc.
Market Cap
$1.54B
Return on Assets (ROA)
20.98%
TTM Avg
9.19%
3Y Avg
12.55%
5Y Avg
16.89%
Market Cap
$1.53B
Return on Assets (ROA)
-25.60%
TTM Avg
-33.58%
3Y Avg
-30.56%
5Y Avg
-19.71%
Market Cap
$1.53B
Return on Assets (ROA)
18.65%
TTM Avg
7.83%
3Y Avg
-23.56%
5Y Avg
-4.38%
Market Cap
$1.51B
Return on Assets (ROA)
10.96%
TTM Avg
-5.00%
3Y Avg
-12.25%
5Y Avg
-27.07%
Market Cap
$1.50B
Return on Assets (ROA)
6.64%
TTM Avg
5.09%
3Y Avg
3.45%
5Y Avg
4.26%
Market Cap
$1.48B
Return on Assets (ROA)
-16.72%
TTM Avg
-18.71%
3Y Avg
-15.50%
5Y Avg
-12.14%
Market Cap
$1.48B
Return on Assets (ROA)
-29.88%
TTM Avg
-23.31%
3Y Avg
-25.68%
5Y Avg
-25.68%
Market Cap
$1.59B
Return on Assets (ROA)
1.96%
TTM Avg
0.34%
3Y Avg
0.01%
5Y Avg
0.90%
Market Cap
$1.61B
Return on Assets (ROA)
-43.15%
TTM Avg
-37.60%
3Y Avg
-124.49%
5Y Avg
-99.59%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Innoviva, Inc. (INVA) | $1.54B | 20.98% | 9.19% | 12.55% | 16.89% |
| uniQure N.V. (QURE)vs › | $1.53B | -25.60% | -33.58% | -30.56% | -19.71% |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 18.65% | 7.83% | -23.56% | -4.38% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 10.96% | -5.00% | -12.25% | -27.07% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.50B | 6.64% | 5.09% | 3.45% | 4.26% |
| GH Research PLC (GHRS)vs › | $1.48B | -16.72% | -18.71% | -15.50% | -12.14% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.48B | -29.88% | -23.31% | -25.68% | -25.68% |
| Omnicell, Inc. (OMCL)vs › | $1.59B | 1.96% | 0.34% | 0.01% | 0.90% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.61B | -43.15% | -37.60% | -124.49% | -99.59% |
| Certara, Inc. (CERT)vs › | $1.46B | -4.89% | -0.43% | -0.87% | -1.37% |
ROA
21.0%
ROE
29.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 16.58% |
| 2024-12-31 | 1.80% |
| 2023-12-31 | 14.45% |
| 2022-12-31 | 17.37% |
| 2021-12-31 | 28.70% |
| 2020-12-31 | 22.45% |
| 2019-12-31 | 21.70% |
| 2018-12-31 | 72.07% |
| 2017-12-31 | 36.52% |
| 2016-12-31 | 15.71% |
| 2015-12-31 | -4.42% |
| 2014-12-31 | -32.29% |
| 2013-12-31 | -25.06% |
| 2012-12-31 | -5.03% |
| 2011-12-31 | -44.57% |
| 2010-12-31 | -25.32% |
| 2009-12-31 | -47.03% |
| 2008-12-31 | -39.65% |
| 2007-12-31 | -98.77% |
| 2006-12-31 | -63.27% |
| 2005-12-31 | -63.68% |
| 2004-12-31 | -35.89% |
| 2003-12-31 | -56.26% |
| 2002-12-31 | -41.11% |
| 2001-12-31 | 0.00% |
| 2000-12-31 | -38.46% |
